KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Randomized, placebo-controlled phase 3 trial evaluating safety, immunogenicity, and reactogenicity of RSVPreF3-Mat in high-risk pregnant women and their infants. PMID 41766205 · Hum Vaccin Immunother · 2026-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Modeling the cost-effectiveness of the next-generation COVID-19 mRNA-1283 vaccine in the United States. PMID 41764030 · J Med Econ · 2026-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States. PMID 41730003 · J Med Econ · 2026-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma. PMID 41701105 · J Med Econ · 2026-Dec This record is an indirect treatment comparison/synthesis of data from multiple trials (PERSEUS, CASSIOPEIA, Myeloma XI), not an original formal report of a single Phase III/IIIb or Phase II/III randomized trial. It does not meet the 'original_result' criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China. PMID 41615771 · Emerg Microbes Infect · 2026-Dec 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial. PMID 41612798 · J Dermatolog Treat · 2026-Dec 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Renin-angiotensin-aldosterone system inhibitors and risk of pancreatic cancer in older adults: A target trial emulation. PMID 41872700 · Int J Cancer · 2026-Aug-15 The record is an observational study using a target trial emulation framework with propensity score matching, not a randomized controlled trial. It does not report a trial phase (Phase II/III or Phase III/IIIb) and is not an original result from a randomized trial. Therefore, it does not meet the criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Key Considerations in Evaluating Syphilis Therapeutics. PMID 42383907 · Sex Transm Dis · 2026-Aug-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-Term Effects of High-Intensity Training after Lung Cancer Surgery-A 5-Yr Follow-Up of a Randomized Controlled Trial. PMID 41851742 · Med Sci Sports Exerc · 2026-Aug-01 The study is a randomized trial in lung cancer patients with survival as a time-to-event endpoint, but it lacks a drug-containing intervention (exercise-based intervention) and does not establish Phase III/IIIb or Phase II/III evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Study on Different Radiation Doses in Neoadjuvant Chemoradiation Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (Neo-DRATEC Trial). PMID 41713514 · Int J Radiat Oncol Biol Phys · 2026-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial. PMID 41622540 · Ther Drug Monit · 2026-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Daratumumab-Based Regimens in Multiple Myeloma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials. PMID 42502279 · EJHaem · 2026-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial. PMID 42456682 · Lancet Neurol · 2026-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21. PMID 42436879 · Blood Neoplasia · 2026-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors. PMID 42433301 · Eur Urol Open Sci · 2026-Aug The record describes the design of a Phase 4 trial (ITALIC-RCC) as a protocol, not a report of results from a Phase III/IIIb or Phase II/III randomized trial. Therefore, it does not meet the eligibility criteria for a result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications. PMID 42427356 · Obes Sci Pract · 2026-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Comparative safety of postoperative HIPEC with recombinant mutant TNF-α versus paclitaxel for gastric cancer peritoneal metastasis: a randomized controlled trial. PMID 42391679 · Surg Oncol · 2026-Aug The study is a randomized trial in gastric cancer with drug intervention, but it is not confirmed as a definitive phase (Phase III/IIIb or II/III) and does not have a primary/key secondary time-to-event efficacy endpoint as the focus; it is primarily a safety study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial. PMID 42383207 · Contemp Clin Trials Commun · 2026-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A systematic review and meta-analysis of long-term outcomes. PMID 42378863 · Surg Oncol · 2026-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Five-year survival after minimally invasive versus open gastrectomy: A meta-analysis of randomized controlled trials with trial sequential analysis. PMID 42364595 · Surg Oncol · 2026-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial. PMID 42364416 · Breast · 2026-Aug The report is a subgroup analysis (exploratory by HER2 status) of a randomized trial. While the trial may be Phase III, this specific publication is not the original formal result report of the primary trial endpoint; it is a pre-specified or exploratory subgroup analysis, which is excluded per the adjudication criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparative efficacy and safety of pathway-targeted pharmacotherapies for Alzheimer's disease: A systematic review and network meta-analysis of phase III trials. PMID 42342156 · Ageing Res Rev · 2026-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. PMID 42330996 · Lancet Gastroenterol Hepatol · 2026-Aug The report presents results from the phase 2 portion of a planned phase 2-3 trial. The primary endpoint was objective response rate, not a time-to-event endpoint like OS or PFS. Although the trial is randomized and involves oncology drugs, it fails the definitive phase and time-to-event endpoint criteria required for inclusion.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Primary results from EL1SSAR, a prospective phase IIIb study of first-line atezolizumab plus nab-paclitaxel therapy for patients with PD-L1-positive advanced triple-negative breast cancer. PMID 42330688 · Breast · 2026-Aug The record describes a single-arm Phase IIIb study. While it meets most other criteria (oncology, human, Phase III, drug intervention, time-to-event endpoints, original results), the absence of randomization makes it ineligible per the specified criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial. PMID 42314722 · Lancet Child Adolesc Health · 2026-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
External vacuum expansion in autologous fat transfer as total breast reconstruction: Is it worth it? The interim analysis of the multicentre randomised controlled EVE trial. PMID 42314328 · J Plast Reconstr Aesthet Surg · 2026-Aug The study is a randomized, oncology-related human trial, but it is excluded because it lacks a primary/key secondary time-to-event efficacy endpoint (like OS, PFS, DFS) and does not involve a drug intervention. The endpoints are volumetric outcomes and safety, which are not time-to-event.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ultra-high dose radiation for Liver metastasis using MR-guided TReatment with stereotactic Ablative Single-fraction (ULTRAS): study protocol for a phase III randomized controlled trial. PMID 42309387 · Contemp Clin Trials · 2026-Aug 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Overall Survival of Patients With PSA-Recurrent Prostate Cancer: Long-Term Analysis of a Randomized Phase 2 Trial of pTVG-HP DNA Vaccine Versus Placebo. PMID 42303538 · Clin Genitourin Cancer · 2026-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Mind the Gap: Impact of New Labels on Public Perceptions and Calculated Risk of Adverse Outcomes after a Melanoma In Situ Diagnosis-A Secondary Analysis of an Online Randomized Experiment. PMID 42289825 · Med Decis Making · 2026-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Strengths and pitfalls of NNT and NNH in early breast cancer escalation trials. PMID 42285001 · Breast · 2026-Aug This is a secondary analysis and synthesis of multiple trials, not an original result report of a single randomized trial. While it discusses trials with drug interventions, the record itself is a methodological commentary, not the primary publication of trial results.
S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. PMID 42251860 · Lancet Diabetes Endocrinol · 2026-Aug 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Delgocitinib cream for adolescents with moderate to severe chronic hand eczema (DELTA TEEN): a multicentre, double-blind, phase 3 randomised controlled trial. PMID 42235562 · Lancet Child Adolesc Health · 2026-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Semaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study. PMID 42219226 · Diabetes Obes Metab · 2026-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial. PMID 42219225 · Diabetes Obes Metab · 2026-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial. PMID 42219222 · Diabetes Obes Metab · 2026-Aug 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules. PMID 42217273 · Clin Genitourin Cancer · 2026-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study. PMID 42186210 · Diabetes Obes Metab · 2026-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis. PMID 42175562 · Clin Pharmacol Ther · 2026-Aug 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A post hoc analysis of BLISS-LN found Belimumab plus mycophenolate mofetil improves kidney outcomes versus placebo plus mycophenolate mofetil in active lupus nephritis. PMID 42173278 · Kidney Int · 2026-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-line immunotherapy with or without PARP inhibitors in advanced ovarian cancer: A meta-analysis including bevacizumab use, molecular status, and PD-L1 expression. PMID 42155872 · Crit Rev Oncol Hematol · 2026-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event Reanalysis. PMID 42150922 · Clin Genitourin Cancer · 2026-Aug This is a secondary, reconstructed-data reanalysis of the LITESPARK-005 trial, not an original formal-result report of a Phase III trial. The metadata does not confirm the trial phase, and the analysis itself is a post-hoc statistical exploration of nonproportional hazards.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pelvic nodes ultra-hypo fractionated versus conventionally fractionated IMRT with HDR brachytherapy in prostate cancer: interim analysis of a collaborative multi-institutional non-inferiority phase 3 trial (PCS-XI, NCT05820633). PMID 42134662 · Radiother Oncol · 2026-Aug The report is an interim analysis of a phase III randomized trial in oncology with a drug intervention (ADT), but it explicitly focuses on toxicity and patient-reported outcomes, not on a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The conclusion states longer follow-up is required to assess oncologic outcomes.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Percutaneous transhepatic biliary drainage versus endoscopic ultrasound-guided biliary drainage with primary metal stenting for unresectable malignant distal biliary obstruction. PMID 42128368 · Endoscopy · 2026-Aug Study is a nonrandomized, non-inferiority trial comparing two procedural interventions (EUS-BD vs. PTBD) with primary metal stenting. It is not a randomized trial of a drug-containing intervention. The primary endpoint was technical success (categorical), but overall survival (a time-to-event endpoint) was also reported. However, the trial is not randomized and does not involve a drug intervention, thus failing key eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Acute and long-term toxicity profiles and final oncologic outcomes in the phase III ARTFORCE trial. PMID 42119642 · Radiother Oncol · 2026-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L S B
旧组与严格 v3 交集 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy induced nausea and vomiting (RINV): CTRI/2022/01/039723. PMID 42119640 · Radiother Oncol · 2026-Aug The trial meets criteria for oncology, human, randomized, phase III, drug intervention, and original result, but the primary and key secondary endpoints are efficacy outcomes (proportion of patients with nausea/vomiting events), not time-to-event endpoints. Therefore, it is excluded from the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial. PMID 42115521 · Diabetes Obes Metab · 2026-Aug This is a secondary analysis of the SPRINT trial focusing on stroke risk in hypertensive patients with prediabetes and cardiac biomarkers. It is not an oncology study, does not involve a drug-containing intervention (SPRINT's intervention was blood pressure target, not a specific drug), and is not a primary trial result but a subgroup analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study. PMID 42108080 · Diabetes Obes Metab · 2026-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Trial. PMID 42098550 · Ann Surg Oncol · 2026-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Intranasal Ketamine for Existential Distress in Advanced Cancer. PMID 42055096 · J Pain Symptom Manage · 2026-Aug The record is an original report of a randomized controlled trial (RCT) in human oncology patients with a drug intervention (ketamine). However, it fails the time-to-event criterion as all reported outcomes are continuous patient-reported or clinician-rated scales (e.g., MADRS, GAD-7, MQOL) without any Kaplan-Meier, hazard ratio, or time-to-event endpoint (OS, PFS, etc.). Additionally, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III, and the publication reports secondary outcomes. Therefore, it is not eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vision-Related Quality of Life in Geographic Atrophy: Association with Topographic Lesion Distribution. PMID 42031134 · Ophthalmology · 2026-Aug 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -